Armata Pharmaceuticals Has Received Additional $5.25M Of Non-dilutive Funding Pursuant To Previously Announced Department Of Defense Grant To Support Development Of Its Optimized Phage Candidate, AP-SA02, For Complicated Staphylococcus Aureus Bacteremia
Portfolio Pulse from Benzinga Newsdesk
Armata Pharmaceuticals has received an additional $5.25 million in non-dilutive funding from a Department of Defense grant to support the development of its phage candidate, AP-SA02, for treating complicated Staphylococcus aureus bacteremia.
July 30, 2024 | 11:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Armata Pharmaceuticals has received an additional $5.25 million in non-dilutive funding from the Department of Defense to support the development of its phage candidate, AP-SA02, for treating complicated Staphylococcus aureus bacteremia.
The additional funding is non-dilutive, meaning it does not affect the company's equity. This financial support from the Department of Defense will help advance the development of AP-SA02, potentially leading to future revenue streams and enhancing the company's product pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100